Table 1 Descriptive summary by number of vaccine dose administered, based on individual measurements.
Number of vaccine doses administered | ||||
|---|---|---|---|---|
3 | 4 | 5 | All | |
(n = 3527) | (n = 2786) | (n = 1063) | (n = 7376) | |
Sex | ||||
Male | 1251 (35.5%) | 893 (32.1%) | 336 (31.6%) | 2480 (33.6%) |
Female | 2276 (64.5%) | 1893 (67.9%) | 727 (68.4%) | 4896 (66.4%) |
Age group (years) | ||||
18–39 | 874 (24.8%) | 345 (12.4%) | 72 (6.8%) | 1291 (17.5%) |
40–59 | 1854 (52.6%) | 1093 (39.2%) | 280 (26.3%) | 3227 (43.8%) |
60–79 | 597 (16.9%) | 960 (34.5%) | 535 (50.3%) | 2092 (28.4%) |
Over 80 | 202 (5.7%) | 388 (13.9%) | 176 (16.6%) | 766 (10.4%) |
Attributes | ||||
General public | 1752 (49.7%) | 1070 (38.4%) | 436 (41.0%) | 3258 (44.2%) |
Resident or staff at elder facility | 696 (19.7%) | 820 (29.4%) | 320 (30.1%) | 1836 (24.9%) |
Health care professional | 1079 (30.6%) | 896 (32.2%) | 307 (28.9%) | 2282 (30.9%) |
Underlying medical conditions | ||||
No | 2248 (63.7%) | 1550 (55.6%) | 557 (52.4%) | 4355 (59.0%) |
Yes | 770 (21.8%) | 1018 (36.5%) | 474 (44.6%) | 2262 (30.7%) |
Missing | 509 (14.4%) | 218 (7.8%) | 32 (3.0%) | 759 (10.3%) |
Immunocompromised or on immunosuppressant medication | ||||
No | 2971 (84.2%) | 2513 (90.2%) | 1013 (95.3%) | 6497 (88.1%) |
Yes | 44 (1.2%) | 54 (1.9%) | 18 (1.7%) | 116 (1.6%) |
Missing | 512 (14.5%) | 219 (7.9%) | 32 (3.0%) | 763 (10.3%) |
Smoking history | ||||
Never-smoker | 2408 (68.3%) | 2106 (75.6%) | 856 (80.5%) | 5370 (72.8%) |
Smoker | 174 (4.9%) | 157 (5.6%) | 83 (7.8%) | 414 (5.6%) |
Former smoker | 449 (12.7%) | 312 (11.2%) | 98 (9.2%) | 859 (11.6%) |
Missing | 496 (14.1%) | 211 (7.6%) | 26 (2.4%) | 733 (9.9%) |
Alcohol consumption history | ||||
Never-drinker | 1885 (53.4%) | 1702 (61.1%) | 697 (65.6%) | 4284 (58.1%) |
Drinker | 31 (0.9%) | 55 (2.0%) | 25 (2.4%) | 111 (1.5%) |
Former drinker | 1116 (31.6%) | 817 (29.3%) | 315 (29.6%) | 2248 (30.5%) |
Missing | 495 (14.0%) | 212 (7.6%) | 26 (2.4%) | 733 (9.9%) |
Vaccine type | ||||
BNT162b2 | 2781 (78.9%) | 1329 (48.3%) | 3 (0.3%) | 4113 (56.1%) |
mRNA1273 | 715 (20.3%) | 830 (30.2%) | 0 (0.0%) | 1545 (21.1%) |
Omicron-compatible BNT162b2 | 25 (0.7%) | 571 (20.8%) | 1024 (96.3%) | 1620 (22.1%) |
Omicron-compatible mRNA1273 | 1 (0.0%) | 20 (0.7%) | 36 (3.4%) | 57 (0.8%) |
Other | 3 (0.1%) | 0 (0.0%) | 0 (0.0%) | 3 (0.0%) |
Days elapsed since vaccination | 188.80 (87.19) | 78.90 (54.19) | 57.08 (31.70) | 128.31 (91.06) |
History of COVID-19 infection | ||||
No | 2914 (82.6%) | 2297 (82.4%) | 868 (81.7%) | 6079 (82.4%) |
Yes | 613 (17.4%) | 489 (17.6%) | 195 (18.3%) | 1297 (17.6%) |
Days elapsed since infection | ||||
No history of infection | 2914 (82.6%) | 2297 (82.4%) | 868 (81.7%) | 6079 (82.4%) |
0–6 days | 2 (0.1%) | 0 (0.0%) | 1 (0.1%) | 3 (0.0%) |
7–89 days | 311 (8.8%) | 235 (8.4%) | 97 (9.1%) | 643 (8.7%) |
90–179 days | 173 (4.9%) | 121 (4.3%) | 39 (3.7%) | 333 (4.5%) |
Over 180 days | 127 (3.6%) | 133 (4.8%) | 58 (5.5%) | 318 (4.3%) |
Prevalent strains at infection | ||||
Original strain | 18 (1.3%) | 20 (2.4%) | 7 (3.3%) | 45 (1.8%) |
Alpha variant | 14 (1.0%) | 15 (1.8%) | 7 (3.3%) | 36 (1.5%) |
Delta variant | 4 (0.3%) | 9 (1.1%) | 3 (1.4%) | 16 (0.7%) |
Omicron variant | 1360 (97.4%) | 800 (94.8%) | 198 (92.1%) | 2358 (96.0%) |
COVID-19 during the study period | ||||
No | 2264 (64.2%) | 2047 (73.5%) | 878 (82.6%) | 5189 (70.3%) |
Yes | 1263 (35.8%) | 739 (26.5%) | 185 (17.4%) | 2187 (29.7%) |
IgG median (interquartile range) | 1406.12(4418.49) | 4465.91(10,465.83) | 7939.61(18,567.65) | 2963.59(8674.88) |
